WO2024184792 - TRANSDERMAL DRUG DELIVERY SYSTEMS FOR ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF APIXABAN AND OTHER DIRECT ORAL ANTICOAGULANTS
National phase entry is expected:
Publication Number
WO/2024/184792
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052081
International Filing Date
04.03.2024
Title **
[English]
TRANSDERMAL DRUG DELIVERY SYSTEMS FOR ADMINISTRATION OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF APIXABAN AND OTHER DIRECT ORAL ANTICOAGULANTS
[French]
SYSTÈMES D'ADMINISTRATION TRANSDERMIQUE DE MÉDICAMENT POUR L'ADMINISTRATION D'UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE D'APIXABAN ET D'AUTRES ANTICOAGULANTS ORAUX DIRECTS
Applicants **
PIKE THERAPEUTICS INC.
250 Howe Street
20th Floor
Vancouver, British Columbia V6C 3R8, CA
Inventors
PLAKOGIANNIS, Fotios M.
157-14 Cryders Lane
Whitestone, New York 11357, US
MODI, Nisarg
32 Logan Avenue
1st Floor
Jersey City, New Jersey 07306, US
PLAKOGIANNIS, Rodoula
38-21 10th Street
Long Island City, New York 11101, US
LATHER, Tamanna
98 Clinton Ave
Jersey City, New Jersey 07306, US
Priority Data
63/450,515
07.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3313 | |
| EPO | Filing, Examination | 52087 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 16835 |
Total: 73341 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Method of preventing and treating thromboembolic conditions by using direct oral anticoagulants such as apixaban via transdermal, subcutaneous, intramuscular or buccal routes by avoiding the gastrointestinal tract.[French]
L'invention concerne un procédé de prévention et de traitement d'états thromboemboliques à l'aide d'anticoagulants oraux directs tels que l'apixaban par voie transdermique, sous-cutanée, intramusculaire ou buccale, en évitant le tractus gastro-intestinal.